MAPT and Alzheimer disease: From a clinical perspective, the occurrence of seeds so early, and prior to neuropathologic change raises questions as to the window within which targeting seed-competent tau might be most therapeutically beneficial, and if such early 3R/4R tau seeds have the pathogenic equivalence of those that occur with late-stage AD neuropathology.